600513 Stock Overview
Manufactures and sells pharmaceuticals, preparations, and API products in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.49 |
| 52 Week High | CN¥14.40 |
| 52 Week Low | CN¥6.71 |
| Beta | 0.43 |
| 11 Month Change | -0.73% |
| 3 Month Change | 13.25% |
| 1 Year Change | -6.04% |
| 33 Year Change | 12.84% |
| 5 Year Change | 31.99% |
| Change since IPO | -4.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.9% | -1.9% | -1.2% |
| 1Y | -6.0% | -5.0% | 3.1% |
Return vs Industry: 600513 underperformed the CN Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: 600513 underperformed the CN Market which returned 5.7% over the past year.
Price Volatility
| 600513 volatility | |
|---|---|
| 600513 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 600513 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600513's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,296 | Ben Niu | www.lhpharma.com |
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and API products in China and internationally. The company offers clopidogrel bisulfate tablets to prevent atherothrombotic events; doxycycline hydrochloride tablets for upper respiratory tract infections, tonsilitis, biliary tract infections, lymphadenitis, cellulitis, and chronic bronchitis; azithromycin tablets for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms; milrinone injection for short-term intravenous therapy in patients with acute compensated heart failure; dapoxetine hydrochloride tablets to treat premature ejaculation; tadafil tablets for erectile dysfunction; and bepotastine besilate tablets. It also provides aiplete tablets to treat benign prostatic hyperplasia; ebastine tablets for allergic rhinitis; felodipine tablets for mild to moderate essential hypertension; drotaverine hydrochloride injection to treat smooth muscle spasms caused by gastrointestinal diseases and to relieve dysmenorrhea; danazol suppositories to treat endometriosis; and terfenadine tablets for allergic rhinitis, perennial allergic rhinitis, and acute and chronic urticaria, as well as preparation products, which covers urinary system, antihistamines, cardiovascular drugs, steroid hormones, and antibiotics.
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Fundamentals Summary
| 600513 fundamental statistics | |
|---|---|
| Market cap | CN¥2.71b |
| Earnings (TTM) | CN¥138.87m |
| Revenue (TTM) | CN¥2.34b |
19.5x
P/E Ratio1.2x
P/S RatioIs 600513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600513 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.34b |
| Cost of Revenue | CN¥1.17b |
| Gross Profit | CN¥1.17b |
| Other Expenses | CN¥1.03b |
| Earnings | CN¥138.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 49.96% |
| Net Profit Margin | 5.95% |
| Debt/Equity Ratio | 51.7% |
How did 600513 perform over the long term?
See historical performance and comparison